SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC.
Nathan A. Pennell
Consultant or Advisory Role - Boehringer Ingelheim; Genentech; Oncogenex; Teva
Research Funding - Astellas Pharma; Pfizer; Roche/Genentech
Joel W. Neal
Research Funding - Roche/Genentech
Jamie E. Chaft
No relevant relationships to disclose
Christopher G. Azzoli
No relevant relationships to disclose
Pasi A. Janne
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Clovis; Genentech; Merrimack Pharmaceuticals ; Pfizer (U); Sanofi
Stock Ownership - GATEKEEPER Pharmaceuticals
Other Remuneration - LabCorp
Ramaswamy Govindan
No relevant relationships to disclose
Tracey L. Evans
Consultant or Advisory Role - Genentech (B)
Research Funding - Genentech
Daniel Botelho Costa
Consultant or Advisory Role - Pfizer; Roche
Rachel Pam Greenerger Rosovsky
No relevant relationships to disclose
Heather A. Wakelee
Research Funding - Roche/Genentech
Rebecca Suk Heist
Research Funding - Genentech; GlaxoSmithKline; Novartis; Pfizer
Alice Tsang Shaw
Consultant or Advisory Role - ARIAD; Chugai Pharma; Genentech; Novartis; Pfizer
Jennifer S. Temel
No relevant relationships to disclose
Marc A. Shapiro
No relevant relationships to disclose
Alona Muzikansky
No relevant relationships to disclose
Michael Lanuti
No relevant relationships to disclose
Thomas James Lynch
Employment or Leadership Position - Bristol-Myers Squibb; Infinity Pharmaceuticals
Consultant or Advisory Role - Boehringer Ingelheim; Roche
Stock Ownership - Bristol-Myers Squibb; Infinity Pharmaceuticals
Other Remuneration - EGFR gene sequencing patent; Partners Healthcare
Mark G. Kris
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim; Roche/Genentech
Lecia V. Sequist
Consultant or Advisory Role - AstraZeneca (U); Boehringer Ingelheim (U); Clovis (U); Merrimack Pharmaceuticals (U)
Research Funding - Genentech